27
Participants
Start Date
August 29, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2027
Peginterferon α-2b injection
Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
Peginterferon α-2b injection
Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
RECRUITING
Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing
RECRUITING
Peking University People's Hospital, Beijing
RECRUITING
Union Hospital affiliated to Fujian Medical University, Fujian
RECRUITING
Nanfang Hospital, Southern Medical University, Guangzhou
RECRUITING
Harbin First Hospital, Harbin
RECRUITING
Henan Cancer Hospital, Henan
RECRUITING
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang
Xiamen Amoytop Biotech Co., Ltd.
INDUSTRY